In the BioHarmony Drug Report Database
Benralizumab
Fasenra (benralizumab) is an antibody pharmaceutical. Benralizumab was first approved as Fasenra on 2017-11-14. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma. It is known to target interleukin-5 receptor subunit alpha.
Trade Name
|
Fasenra |
|---|---|
Common Name
|
benralizumab |
ChEMBL ID
|
CHEMBL1742991 |
Indication
|
asthma |
Drug Class
|
Monoclonal antibodies: humanized, immunomodulating |
Image (chem structure or protein)
